Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

The medications are so common now, two-thirds of the clinic’s calls for insurance pre-authorizations are for the big three: ...

The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to ... Along with Novo Nordisk's GLP-1 drugs Ozempic and Wegovy, this class of ...

But a recent head-to-head trial comparing Zepbound vs. Wegovy provided new insights into their effectiveness, making the choice slightly clearer. The findings? Zepbound led to an average weight ...

Alcoa reported Q3 2024 EPS of 57 cents, beating consensus estimates of 25 cents by 32 cents. Revenues rose 11.6% YoY to $2.90 ...

Pharmaceutical giant Eli Lilly that new preliminary research indicates its medication Zepbound helps patients lose more weight in a shorter time frame compared to Novo Nordisk's Wegovy.